IBO Stock Overview
Impact BioMedical Inc. focused on discovery, development, and commercialization of products and technologies to address unmet needs in human healthcare and wellness for specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness products in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Impact BioMedical Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.21 |
| 52 Week High | US$3.00 |
| 52 Week Low | US$1.22 |
| Beta | 0 |
| 11 Month Change | 10.50% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -17.54% |
Recent News & Updates
Recent updates
Shareholder Returns
| IBO | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 38.1% | -3.7% | 0.5% |
| 1Y | n/a | 22.6% | 36.8% |
Return vs Industry: Insufficient data to determine how IBO performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how IBO performed against the US Market.
Price Volatility
| IBO volatility | |
|---|---|
| IBO Average Weekly Movement | 23.4% |
| Pharmaceuticals Industry Average Movement | 9.4% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: IBO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine IBO's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 1 | Frank Heuszel | www.impactbiomedinc.com |
Impact BioMedical Inc. focused on discovery, development, and commercialization of products and technologies to address unmet needs in human healthcare and wellness for specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness products in the United States. The company provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application in oncology, inflammatory disorders, and neurology; and Laetose technology that is derived from a unique combination of sugar and inositol, which can inhibit the inflammatory and metabolic response of sugar alone. It also develops functional fragrance formulation, a suite of functional fragrances containing specialized botanical ingredients with application as an antimicrobial, and as an additive in insect repellents, detergents, lotions, shampoo, fabrics, and other substances.
Impact BioMedical Inc. Fundamentals Summary
| IBO fundamental statistics | |
|---|---|
| Market cap | US$24.84m |
| Earnings (TTM) | -US$4.25m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-6.0x
P/E RatioIs IBO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IBO income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$4.25m |
| Earnings | -US$4.25m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.37 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 51.0% |
How did IBO perform over the long term?
See historical performance and comparison